Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2002

01-11-2002 | Review

Current status of the molecular mechanisms of anticancer drug-induced apoptosis

The contribution of molecular-level analysis to cancer chemotherapy

Authors: Ryungsa Kim, Kazuaki Tanabe, Yoko Uchida, Manabu Emi, Hideki Inoue, Tetsuya Toge

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2002

Login to get access
Metadata
Title
Current status of the molecular mechanisms of anticancer drug-induced apoptosis
The contribution of molecular-level analysis to cancer chemotherapy
Authors
Ryungsa Kim
Kazuaki Tanabe
Yoko Uchida
Manabu Emi
Hideki Inoue
Tetsuya Toge
Publication date
01-11-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-002-0522-7

Other articles of this Issue 5/2002

Cancer Chemotherapy and Pharmacology 5/2002 Go to the issue

Original Article

Toxicity of intracranial and intraperitoneal O6-benzyl guanine in combination with BCNU delivered locally in a mouse model

Original Article

Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells

Short Communication

Carboplatin hypersensitivity presenting as coronary vasospasm – a case report

Original Article

Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines

Original Article

High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer

Original Article

Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits